Brigatinib
- Generic Name
- Brigatinib
- Brand Names
- Alunbrig
- Drug Type
- Small Molecule
- Chemical Formula
- C29H39ClN7O2P
- CAS Number
- 1197953-54-0
- Unique Ingredient Identifier
- HYW8DB273J
- Background
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal ...
- Indication
The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT03737994
- Locations
- 🇺🇸
Miller-Dwan Hospital, Duluth, Minnesota, United States
🇺🇸Fairview Southdale Hospital, Edina, Minnesota, United States
🇺🇸Grady Memorial Hospital, Delaware, Ohio, United States
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT03719898
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT03707938
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 248
- Registration Number
- NCT03596866
- Locations
- 🇦🇷
Sanatorio Duarte Quiros, Cordoba, Argentina
🇨🇳Peking Union Medical College Hospital - East, Beijing, Beijing, China
🇨🇱Centro de Investigacion Clinica Bradford Hill, Recoleta, Santiago, Chile
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 111
- Registration Number
- NCT03546894
- Locations
- 🇺🇸
EmpiraMed, Inc., Maynard, Massachusetts, United States
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Ariad Pharmaceuticals
- Target Recruit Count
- 103
- Registration Number
- NCT03535740
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Jilin Provincial Cancer Hospital (Changchun Cancer Hospital), Changchun, Jilin, China
🇨🇳Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT03420742
- Locations
- 🇫🇷
Hopital de la Timone, Marseille, Provence Alpes COTE D'azur, France
🇮🇹Policlinico Sant'Orsola Malpighi, Bologna, Italy
🇮🇹Ospedale San Raffaele, Milano, Italy
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 104
- Registration Number
- NCT03410108
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵Kurume University Hospital, Kurume, Fukuoka, Japan
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Ariad Pharmaceuticals
- Registration Number
- NCT02784158
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center (Site 099), La Jolla, California, United States
🇺🇸Karmanos Cancer Institute (Site 070), Detroit, Michigan, United States
🇺🇸UCI Medical Center-Chao Family Comprehensive (Site 210), Orange, California, United States
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
- Conditions
- Interventions
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Ariad Pharmaceuticals
- Target Recruit Count
- 275
- Registration Number
- NCT02737501
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇦🇺Monash Medical Centre, Bentleigh East, Victoria, Australia
🇦🇹Universitatsklinium St. Polten, Sankt Polten, Lower Austria, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.